Skip to content

The Turkish Version of the Vividness of Visual Imagery Questionnaire-2

The Turkish Version of the Vividness of Visual Imagery Questionnaire-2

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04335903
Enrollment
248
Registered
2020-04-07
Start date
2021-08-21
Completion date
2022-01-21
Last updated
2024-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Assessment, Self, Body Image

Keywords

Imagination, Motor imagery, Body Image, Kinesthesis

Brief summary

The Vividness of Visual Imagery Questionnaire-2 (VMIQ-2) is originally developed in English to determine the vividness of visual imagery. The purpose of this study is to translate and cross-culturally adapt the VMIQ instrument into Turkish and investigate its psychometric properties.

Detailed description

The Vividness of Visual Imagery Questionnaire-2 (VMIQ-2) was originally developed in English to determine the vividness of visual imagery. The purpose of this study is to translate and cross-culturally adapt the VMIQ-2 instrument into Turkish and investigate its psychometric properties. One hundred fifty healthy participants will be included. For cross-cultural adaptation, two bi-lingual translators will use the back-translation procedure. Within a 5-to-7-day period after the first assessment, the participants will complete the Turkish version of VMIQ (VMIQ-2-T) to evaluate test-retest reliability. Cronbach's alpha (α) will use to assess internal consistency. The correlation with the Turkish version of Kinesthetic and Visual Imagery Questionnaire-20 will be determined to check the validity.

Interventions

None listed

Sponsors

Istanbul University - Cerrahpasa
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* age over 18 years old * ability to read and write in Turkish * no pathology in visual ability and hearing * able to follow simple instructions

Exclusion criteria

* having a chronic disease * severe musculoskeletal, neurological or cardiovascular disorders that limit mobility * having any cognitive problem

Design outcomes

Primary

MeasureTime frameDescription
The Vividness of Visual Imagery Questionnaire-2Baseline (First assessment)This questionnaire is composed of 12 items - walking, running, kicking a stone, bending down to pick up a coin, running up stairs, jumping sideways, throwing a stone into water, kicking a ball in the air, running downhill, riding a bike, swinging on a rope, and jumping off a high wall. It requires individuals to imagine themselves performing the 12 items, from three imagery perspectives: internal visual imagery (a first-person perspective), external visual imagery (a third-person perspective), and kinesthetic imagery (feeling the movement).

Secondary

MeasureTime frameDescription
The Vividness of Visual Imagery Questionnaire-2Within a 5-to-7-day period after the first assessment (Second assessment)This questionnaire is composed of 12 items - walking, running, kicking a stone, bending down to pick up a coin, running up stairs, jumping sideways, throwing a stone into water, kicking a ball in the air, running downhill, riding a bike, swinging on a rope, and jumping off a high wall. It requires individuals to imagine themselves performing the 12 items, from three imagery perspectives: internal visual imagery (a first-person perspective), external visual imagery (a third-person perspective), and kinesthetic imagery (feeling the movement).
The Movement Imagery Questionnaire-3Baseline (First assessment)This questionnaire is composed of 4 items and requires individuals to imagine themselves performing the 4 items, from three imagery perspectives: internal visual imagery (a first-person perspective), external visual imagery (a third-person perspective), and kinesthetic imagery (feeling the movement).

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026